TriangleHEALTH PROFESSIONAL · SOURCE READING
Sorafenib
Source: Renal Cell Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 13, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Sorafenib is an orally available multikinase inhibitor (CRAF, BRAF, KIT, FLT-3, VEGFR-2, VEGFR-3, and PDGFRB) and has also been approved for the treatment of patients with advanced renal cell carcinoma.[58]
Source links and citations
Evidence (sorafenib):
In an international, multicenter, randomized trial, 769 patients were stratified by the Memorial Sloan Kettering Cancer Center prognostic risk category and by country. Patients were randomly assigned to receive either sorafenib (400 mg bid) or a placebo. Approximately 82% of the patients had received IL-2 previously and/or interferon alfa in both arms of the study. The primary end points were PFS and OS.
In an international, multicenter, randomized trial, 769 patients were stratified by the Memorial Sloan Kettering Cancer Center prognostic risk category and by country. Patients were randomly assigned to receive either sorafenib (400 mg bid) or a placebo. Approximately 82% of the patients had received IL-2 previously and/or interferon alfa in both arms of the study. The primary end points were PFS and OS.
The median PFS for patients randomly assigned to sorafenib was 167 days compared with 84 days for patients randomly assigned to placebo (P < .001).
In an international, multicenter, randomized trial, 769 patients were stratified by the Memorial Sloan Kettering Cancer Center prognostic risk category and by country. Patients were randomly assigned to receive either sorafenib (400 mg bid) or a placebo. Approximately 82% of the patients had received IL-2 previously and/or interferon alfa in both arms of the study. The primary end points were PFS and OS.
The estimated HR for the risk of progression with sorafenib compared with a placebo was 0.44 (95% CI, 0.35–0.55). There was no significant difference in OS.[58][Level of evidence B1]
Source links and citations
A phase II study randomly assigned 189 patients to either sorafenib or interferon alfa.[29]
Source links and citations
A phase II study randomly assigned 189 patients to either sorafenib or interferon alfa.[29]
No difference was reported in PFS (5.7 months vs. 5.6 months), but sorafenib was associated with better QOL than interferon alfa.
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice